ASSET PURCHASE AND LICENSE AMENDMENT AGREEMENTAsset Purchase and License Amendment Agreement • December 27th, 2022 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Asset Purchase and License Amendment Agreement (this “Agreement”), dated as of December 27, 2022 (the “Agreement Date”), is entered into by and between Jounce Therapeutics, Inc., a Delaware corporation (“Seller”), and Gilead Sciences, Inc., a Delaware corporation (“Buyer,” and with Seller, individually, each a “Party” and, collectively, the “Parties”). Any capitalized term not defined herein that is defined in the License Agreement (as defined below) shall have the meaning set forth in the License Agreement.
